Targeting chromatin remodelers to treat hepatocellular carcinoma
Manlio Vinciguerra – 28 June 2012
Low rates of naturally occurring resistant variants to the NS5A inhibitor daclatasvir in HCV‐1 null responders
Enrico Galmozzi, Alessio Aghemo, Massimo Colombo – 28 June 2012
Cognitive dysfunction, falls and helicobacter pylori in cirrhosis
German Soriano, Eva Román, Joan Córdoba – 28 June 2012
Helicobacter pylori induced cognitive dysfunction might be associated with falls and fractures in cirrhosis
Jannis Kountouras, Christos Zavos, Georgia Deretzi, Elizabeth Vardaka, Marina Boziki, Emmanouel Gavalas, George Kouklakis, Panagiotis Katsinelos, Ioannis Venizelos, Christina Nikolaidou, Stergios A. Polyzos, Evaggelia Giartza‐Taxidou – 28 June 2012
Impact of cohort size and host factors on combined analysis of interleukin 28B rs12979860 and rs8099917 in hepatitis C virus infection
Janett Fischer, Stephan Böhm, Jacob George, Christoph Sarrazin, Thomas Berg – 28 June 2012
Is there need for more than one IL28B single nucleotide polymorphism in hepatitis C clinical practice?
Enrico Galmozzi, Stella De Nicola, Alessio Aghemo, Massimo Colombo – 28 June 2012
Hepatitis B virus X protein stimulates gene expression selectively from extrachromosomal DNA templates
Pieter C. van Breugel, Eva I. Robert, Henrik Mueller, Adrien Decorsière, Fabien Zoulim, Olivier Hantz, Michel Strubin – 28 June 2012 – Chronic hepatitis B virus (HBV) infection is a major risk factor for liver cancer development. HBV encodes the hepatitis B virus X (HBx) protein that promotes transcription of the viral episomal DNA genome by the host cell RNA polymerase II. Here we provide evidence that HBx accomplishes this task by a conserved and unusual mechanism.
Evolution of nonalcoholic fatty liver disease recurrence after liver transplantation
- Read more about Evolution of nonalcoholic fatty liver disease recurrence after liver transplantation
Deepa T. Patil, Lisa M. Yerian – 27 June 2012 – Nonalcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease (NAFLD) and is the fourth most common indication for liver transplantation. Risk factors for NAFLD can persist and even worsen after liver transplantation. However, the risk and significance of NAFLD recurrence remain unclear. Reported posttransplant NAFLD and NASH recurrence rates vary widely across studies.
Rapid recovery of cytochrome P450 3A4 after protease inhibitor withdrawal in post–liver transplant patients
Ye Htun Oo, David J. Mutimer – 27 June 2012
ImmuKnow as a diagnostic tool for predicting infection and acute rejection in adult liver transplant recipients: A systematic review and meta‐analysis
Emilio Rodrigo, Marcos López‐Hoyos, Mario Corral, Emilio Fábrega, Gema Fernández‐Fresnedo, David San Segundo, Celestino Piñera, Manuel Arias – 27 June 2012 – Immune status monitoring of transplant recipients could identify patients at risk of acute rejection, infection, and cancer, which are important sources of morbidity and mortality in these patients. The ImmuKnow assay provides an objective assessment of the cellular immune function of immunosuppressed patients.